IL33 and acute graft versus host disease: In acute graft-versus-host disease after allogeneic hematopoietic cell transplantation, IL-33 administered during the peak of the inflammatory response increased type 1 cytokine expression and aggravated mortality [163] whereas IL-33 treatment before body irradiation expanded ST2+ Tregs and accelerated acute lethality [164].